Lilly expects to soon announce late-stage clinical trial results for two biotech drugs designed to slow the inflammation caused by autoimmune diseases. By the end of the year, it will announce results for a third.
The once-booming toxicology business struggled for years under declining revenue and huge debts before being acquired last year by a Texas private equity firm. Its Park Fletcher headquarters building remains empty.
Gov.-elect Eric Holcomb, who announced his legislative agenda Thursday, has roughly the same idea as Gov. Mike Pence when it comes to investing in early-stage Indiana companies, but wants to pay for the plan through a different fund.